0.00Open21.60Pre Close0 Volume0 Open Interest45.00Strike Price0.00Turnover0.00%IV-61.71%PremiumJan 17, 2025Expiry Date30.53Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Dyne Therapeutics Stock Discussion
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics (Nasdaq: DYN) has received FDA Fast Track designation for DYNE-101, their treatment candidate for myotonic dystrophy type 1 (DM1). The designation follows positive clinical data from their ongoing Phase 1/2 ACHIEVE global trial, which showed substantial functional benefits and splicing correction in patients.
The company plans to su...
Dyne Therapeutics Receives FDA Fast Track Designation for Dyne-101 for the Treatment of Myotonic Dystrophy Type 1
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...
GlobeNewswire· 7 mins ago
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
- DYNE-101 Showed Improvement in Myotonia, Muscle Strength, ...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$